Influenza Market Size, Share, Trends, Growth Outlook

Influenza Market is estimated to increase at a growth rate of 7.1% CAGR over the forecast period from 2024 to 2030.

The global Influenza Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Vaccines, Drugs), By Age Group (Children, Adults).

An Introduction to Influenza Market in 2024

The Influenza Market comprises diagnostics, vaccines, antiviral drugs, and therapeutics used for preventing, diagnosing, and managing influenza, a contagious respiratory viral infection causing seasonal flu outbreaks worldwide. This market includes rapid influenza tests, influenza vaccines, neuraminidase inhibitors, M2 inhibitors, and combination therapies used in healthcare settings, pharmacies, and community clinics. Innovations in influenza management focus on universal vaccines, pandemic preparedness, antiviral resistance surveillance, point-of-care testing, and immunization strategies to combat seasonal flu strains, reduce influenza-related complications, and enhance influenza prevention and control efforts globally.

Influenza Market Competitive Landscape

The global Influenza Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Influenza Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Influenza Industry include- Abbott Laboratories, AstraZeneca Plc, CSL Ltd, F. Hoffmann-La Roche, GlaxoSmithKline Plc, Merck & Co., Mitsubishi Tanabe Pharma Corp, Novartis AG, Pfizer Inc, Sanofi S.A..

Influenza Market Trend: Increased Focus on Preventive Measures and Vaccination Programs

One prominent trend in the influenza market is the heightened focus on preventive measures and vaccination programs. With the recurring threat of seasonal influenza outbreaks and the potential for pandemics, governments, healthcare organizations, and pharmaceutical companies are emphasizing the importance of vaccination as a primary preventive measure. This trend is driving the demand for influenza vaccines and related products, leading to significant market growth opportunities.

Influenza Market Driver: Technological Innovations in Influenza Diagnostics and Treatment

A key driver of the influenza market is the continuous technological innovations in diagnostics and treatment options. Advancements such as rapid influenza diagnostic tests (RIDTs), point-of-care testing devices, and antiviral therapies are enhancing the speed and accuracy of influenza diagnosis and management. Additionally, research into novel treatment modalities such as monoclonal antibodies and universal influenza vaccines is fueling market expansion by offering more effective and convenient solutions for both healthcare providers and patients.

Influenza Market Opportunity: Expansion of Distribution Channels and Access to Rural Areas

An opportunity in the influenza market lies in the expansion of distribution channels and improving access to rural and underserved areas. Despite the availability of vaccines and treatments, disparities in access persist, particularly in remote regions with limited healthcare infrastructure. By investing in distribution networks, telemedicine solutions, and community outreach programs, stakeholders can bridge the gap and ensure broader access to influenza prevention and management tools, thereby maximizing market penetration and public health impact.

Influenza Market Share Analysis: Influenza Vaccines - Live Attenuated is the fastest growing market segment over the forecast period to 2030

Within the realm of influenza products, the Live Attenuated Influenza Vaccine (LAIV) segment is experiencing the fastest growth. LAIV offers a unique approach to influenza prevention by introducing weakened forms of the influenza virus into the body, stimulating an immune response without causing illness. This method is particularly advantageous for certain demographics, such as children and individuals with needle phobia, as LAIV is administered through a nasal spray rather than an injection. The convenience and efficacy of LAIV have led to its increasing adoption in pediatric vaccination programs and community-based influenza prevention efforts. Moreover, ongoing research and development efforts aimed at improving LAIV formulations and broadening its coverage against diverse influenza strains are further driving its growth. As public health agencies emphasize the importance of annual influenza vaccination and seek to overcome barriers to vaccine uptake, the popularity and demand for LAIV are expected to continue rising, making it a key player in the fight against influenza.

Influenza Market Segmentation

By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Influenza Companies

Abbott Laboratories
AstraZeneca Plc
CSL Ltd
F. Hoffmann-La Roche
GlaxoSmithKline Plc
Merck & Co.
Mitsubishi Tanabe Pharma Corp
Novartis AG
Pfizer Inc
Sanofi S.A.
* List not Exhaustive

Reasons to Buy the Influenza Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Influenza Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Influenza Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Influenza Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Influenza Market Size Outlook, $ Million, 2021 to 2030
3.2 Influenza Market Outlook by Type, $ Million, 2021 to 2030
3.3 Influenza Market Outlook by Product, $ Million, 2021 to 2030
3.4 Influenza Market Outlook by Application, $ Million, 2021 to 2030
3.5 Influenza Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Influenza Industry
4.2 Key Market Trends in Influenza Industry
4.3 Potential Opportunities in Influenza Industry
4.4 Key Challenges in Influenza Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Influenza Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Influenza Market Outlook by Segments
7.1 Influenza Market Outlook by Segments, $ Million, 2021- 2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
8 North America Influenza Market Analysis and Outlook To 2030
8.1 Introduction to North America Influenza Markets in 2024
8.2 North America Influenza Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Influenza Market size Outlook by Segments, 2021-2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
9 Europe Influenza Market Analysis and Outlook To 2030
9.1 Introduction to Europe Influenza Markets in 2024
9.2 Europe Influenza Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Influenza Market Size Outlook by Segments, 2021-2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
10 Asia Pacific Influenza Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Influenza Markets in 2024
10.2 Asia Pacific Influenza Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Influenza Market size Outlook by Segments, 2021-2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
11 South America Influenza Market Analysis and Outlook To 2030
11.1 Introduction to South America Influenza Markets in 2024
11.2 South America Influenza Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Influenza Market size Outlook by Segments, 2021-2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
12 Middle East and Africa Influenza Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Influenza Markets in 2024
12.2 Middle East and Africa Influenza Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Influenza Market size Outlook by Segments, 2021-2030
By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
AstraZeneca Plc
CSL Ltd
F. Hoffmann-La Roche
GlaxoSmithKline Plc
Merck & Co.
Mitsubishi Tanabe Pharma Corp
Novartis AG
Pfizer Inc
Sanofi S.A.
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Vaccines
-Inactivated
-Live Attenuated
Drugs
By Age Group
Children
Adults